Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25560260 | 0.85 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL3967577 | 0.83 | KDM4E (0.40) | KDM4EALDH1A1LMNAHPGDGLA | |
| SCHEMBL13829027 | 0.83 | MAPK14 (0.40) | LMNAMAPTPDK1HSP90AA1PDK2 | |
| SCHEMBL12813257 | 0.82 | AXL (0.47) | SMN1; SMN2PDK1PDK2PDK4CYP1A2 | |
| SCHEMBL16585820 | 0.81 | PDK1 (0.40) | KDM4EALDH1A1LMNAHPGDGLA | |
| SCHEMBL22529466 | 0.81 | PDK1 (0.49) | PDK1HSP90AA1PDK2PDK4 | |
| SCHEMBL12813116 | 0.81 | MAPK14 (0.42) | PDK1HSP90AA1PDK2PDK4 | |
| SCHEMBL30444276 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1LMNAHPGDGLA | |
| SCHEMBL2611837 | 0.80 | MAPT (0.57) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL25820968 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1LMNAHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4725485-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | Jilin University (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-119285557-A | CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof | 吉林大学 | 2025-01-10 | — | — | CN | disclosed |
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| CN-103864770-B | Aminopyrimidine and pyridyl amine inhibitor as Hedgehog signal transduction | 江苏先声药业有限公司 | 2019-06-11 | — | — | CN | disclosed |
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| CN-101309918-B | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI | 2010-12-29 | — | — | CN | disclosed |
| CN-101309918-A | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | KDM4E 4808/4885ALDH1A1 1158/4885LMNA 4048/4885 |
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | GZMB, CD74, GSDMD | KDM4E 520/4885ALDH1A1 3962/4885LMNA 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.